Q-omics provides the consensus-scored GAPDHP48 profile across patient tissues and cancer cell-line models. GAPDHP48 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GAPDHP48 is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, GAPDHP48 RNA expression shows 5,404 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KICH, HNSC, and KIRC as cancer lineages where GAPDHP48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GAPDHP48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GAPDHP48 survival associations across molecular data types. GAPDHP48 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GAPDHP48 RNA expression–survival associations across cancer types. High GAPDHP48 expression shows unfavorable associations in KICH, CHOL, THCA, MESO and UVM, but favorable associations in LUSC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GAPDHP48 RNA expression.
This table summarizes GAPDHP48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GAPDHP48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GAPDHP48 shows lower tumor expression in KIRC and LIHC and higher tumor expression in HNSC, BLCA and PRAD. The HNSC box plot shows higher GAPDHP48 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .003).
This table shows molecular features associated with GAPDHP48 in patient tissues and cancer cell lines. In patient samples, GAPDHP48 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
